Product nameAnti-Prosurfactant Protein C antibody
See all Prosurfactant Protein C primary antibodies
DescriptionRabbit polyclonal to Prosurfactant Protein C
Tested applicationsSuitable for: WB, ICC/IF, IHC-Pmore details
Species reactivityReacts with: Human
Recombinant full length protein corresponding to Human SFTPC.
Database link: P11686
- U2OS cells; Jurkat, U937 and Raji cell extracts.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, 49% PBS
PBS without Mg2+ and Ca2+.
Concentration information loading...
PurityImmunogen affinity purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
Our Abpromise guarantee covers the use of ab196677 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/2000. Predicted molecular weight: 21 kDa.|
|ICC/IF||1/50 - 1/200.|
|IHC-P||1/50 - 1/100.|
FunctionPulmonary surfactant associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces.
Involvement in diseaseDefects in SFTPC are the cause of pulmonary surfactant metabolism dysfunction type 2 (SMDP2) [MIM:610913]; also called pulmonary alveolar proteinosis due to surfactant protein C deficiency. A rare disease associated with progressive respiratory insufficiency and lung disease with a variable clinical course, due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress.
Genetic variations in SFTPC are a cause of susceptibility to respiratory distress syndrome in premature infants (RDS) [MIM:267450]; also known as RDS in prematurity. RDS is a lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high-permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'.
Sequence similaritiesContains 1 BRICHOS domain.
Cellular localizationSecreted > extracellular space > surface film.
- Information by UniProt
- BRICD6 antibody
- BRICHOS domain containing 6 antibody
- PSP C antibody
All lanes : Anti-Prosurfactant Protein C antibody (ab196677) at 1/500 dilution
Lane 1 : Jurkat cell extract
Lane 2 : U937 cell extract
Lane 3 : Raji cell extract
Predicted band size: 21 kDa
Immunofluorescent analysis of U2OS cells labeling SFTPC with ab196677 at 1/50 dilution. Lower image with DAPI for nuclear staining.